NELL-1/DBM Combination Product
Spinal Fusion (Posterolateral Lumbar)
Key Facts
About Bone Biologics
Bone Biologics is a clinical-stage biotech focused on developing novel, targeted biologic therapeutics for bone regeneration, with an initial focus on spinal fusion. Its core asset is the recombinant human NELL-1 protein, engineered to be a potent and selective osteoinductive agent that may offer safety advantages over historical BMPs. The company's strategy is to advance its lead NELL-1/DBM combination product through clinical trials to address a significant unmet need in orthopedic surgery. As a micro-cap public entity, it operates with a lean structure, directing resources toward key clinical milestones.
View full company profile